← Back to Search

Cancer Vaccine

Vaccination with Prevnar. for Aging

Phase 4

Recruiting

Led By Elsa N Bou Ghanem, PhD

Research Sponsored by State University of New York at Buffalo

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Have not been vaccinated with any licensed or experimental pneumococcal vaccine

Did not take any anti-inflammatory medicine in the last week

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 month

Awards & highlights

Study Summary

This trial investigates how a type of white blood cell called neutrophils affects the body's response to the Prevnar-13 vaccine for pneumonia in both young and elderly adults.

Who is the study for?

This trial is for adults aged 21-40 and those over 65 who haven't had alcohol in the last day, avoided anti-inflammatory meds in the past week, and have not been vaccinated against pneumococcal diseases. They must be able to consent and free of recent infections.Check my eligibility

What is being tested?

The study is examining how neutrophils affect immune responses to Prevnar-13, an anti-pneumococcal vaccine, comparing younger adults with elderly individuals to understand age-related changes.See study design

What are the potential side effects?

While specific side effects are not listed here, common reactions to vaccines like Prevnar-13 can include redness or swelling at the injection site, mild fever, fatigue, headache, chills or muscle pain.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have never received a pneumococcal vaccine.

Select...

I haven't taken any anti-inflammatory medicine in the past week.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 month

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 month

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Pneumococcal Opsonophagocytic Killing Activity (OPH) by neutrophils from young versus old donors at 1 week and 1 month after vaccination

Secondary outcome measures

Surface phenotype of neutrophils from young versus old donors at 1 week and 1 month after vaccination

Trial Design

1Treatment groups

Experimental Treatment

Group I: Vaccination with Prevnar.Experimental Treatment1 Intervention

Intramuscular vaccination with Prevnar 20

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Institute on Aging (NIA)NIH

1,675 Previous Clinical Trials

28,020,825 Total Patients Enrolled

160 Trials studying Aging

75,947 Patients Enrolled for Aging

State University of New York at BuffaloLead Sponsor

246 Previous Clinical Trials

49,448 Total Patients Enrolled

1 Trials studying Aging

16 Patients Enrolled for Aging

Elsa N Bou Ghanem, PhDPrincipal InvestigatorUniversity at Buffalo

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any ongoing opportunities for patient enrollment in this clinical trial at the moment?

"According to the details provided on clinicaltrials.gov, this investigation is currently in search of eligible candidates. The trial was initially published on January 8th, 2024 and underwent its most recent revision on February 5th, 2024."

Answered by AI

Has Prevnar been validated by the FDA for vaccination use?

"Given that this is a Phase 4 trial, indicating the treatment has gained approval, our Power team rates the safety of Prevnar vaccination at the highest level of 3."

Answered by AI

What is the current number of participants being recruited for this research project?

"Indeed, information available on clinicaltrials.gov indicates that patient recruitment is ongoing for this investigation. The trial was initially listed on January 8th, 2024, with the most recent update posted on February 5th of the same year. Recruitment targets include enrolling a total of 60 participants at one designated research site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses

Elsa Bou Ghanem 2024. "The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06128915.